(redirected from autologous bone marrow transplantation)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
Related to autologous bone marrow transplantation: Hematopoietic stem cell transplantation
References in periodicals archive ?
High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission.
Randomised comparison of addition of autologous bone marrow transplantation to intensive chemotherapy for acute myeloid leukemia in first remission: results of MRC AML 10 trial.
A total of 113 patients had suitable donors for allogeneic bone marrow transplantation; the others were randomly assigned to either autologous bone marrow transplantation or to a single course of high-dose cytarabine.
Blue Cross Blue Shield of New Jersey, involved a suit over denial of coverage of autologous bone marrow transplantation.
The increased charges associated with the prolonged hospital stay ranged from $14,772 for an increase of just two hospital days for an allogeneic bone marrow transplant to $24,068, an increase of 10 hospital days, for an autologous bone marrow transplantation.
Although autologous bone marrow transplantation is currently employed in the treatment of acute leukemia and multiple myeloma, relapse rates remain unacceptably high.
This is illustrated clearly by recent adverse decisions against Blue Cross/Blue Shield plans in cases regarding autologous bone marrow transplantation and a queue of suits facing Blue Cross/Blue Shield plans across the country.
FDA clearance of the CEPRATE SC System was based on a Phase III clinical trial in autologous bone marrow transplantation for patients with breast cancer.
The six patients had either acute myelogenous leukemia (AML) or non-Hodgkins lymphoma that had not responded to all previous treatment regimens including chemotherapy, radiation and/or autologous bone marrow transplantation.
This year, the DATTA program is reevaluating autologous bone marrow transplantation, percutaneous diskectomy, and transrectal ultrasound of the prostate.
It is used to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever and, in June 1994, was approved to reduce the duration of neutropenia following allogeneic and autologous bone marrow transplantation.
Nasdaq: ASTM) announced today that it has been awarded another Phase I Small Business Innovation and Research (SBIR) grant to support the development of techniques for the ex vivo generation of cells for use in accelerating platelet regeneration in cancer patients following autologous bone marrow transplantation.

Full browser ?